Atara Shares Sink After FDA Stalls Cancer Treatment
Atara Biotherapeutics shares plunged after the FDA rejected its application to bring a blood cancer treatment to market. Shares of the biotechnology company were recently down 46.5% to $7.04. The ...
Targeted Oncology55m
FDA Approves Axatilimab for Chronic GVHD in New Vial Sizes
Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...
Atara stock plummets on FDA setback for EBV drug
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) tumbled 51% after the company disclosed receiving a Complete Response ...